1-4 of 4
Alejandro Arbelaez
Close
Sort by
Journal Articles

Preliminary Safety and Efficacy Data from Patients (Pts) with Relapsed/Refractory (R/R) B-Cell Malignancies Treated with the Novel B-Cell Lymphoma 2 (BCL2) Inhibitor BGB-11417 in Monotherapy or in Combination with Zanubrutinib

Constantine S. Tam, Emma Verner, Masa Lasica, Alejandro Arbelaez, Peter J. Browett, Jacob D. Soumerai, James Hilger, Yiqian Fang, Jane Huang, David Simpson, Stephen Opat, Chan Yoon Y. Cheah
Journal: Blood
Blood (2021) 138 (Supplement 1): 1419.
https://doi.org/10.1182/blood-2021-148451
Published: 2021
Journal Articles

A Phase 2, Open-Label, Ascending Dose Study of Ker-050 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes

David M Ross, Alejandro Arbelaez, Lynette C.Y. Chee, Chun Yew Fong, Devendra Hiwase, George Kannourakis, John Kwan, James Liang, Anish Puliyayil, Hannah Rose, Shuhying Tan, Tse-Chieh Teh, David Alan Westerman, Joel Wight, Chris Rovaldi, Elissa M. Furutani, Adrienne Gaggi, Ying Jiang, Jenn Lachey, Harveen Dhillon Natarajan, Claudia Ordonez
Journal: Blood
Blood (2021) 138 (Supplement 1): 3675.
https://doi.org/10.1182/blood-2021-147335
Published: 2021
Journal Articles

Breast Implant Related Anaplastic Large Cell Lymphoma ALK- (ALCL ALK-) – Case Report

Alejandro Arbelaez, MBBS, Laurence Catley, MBBS, FRCPA, FRACP, Louis Pool, MBBS, FRCPA
Journal: Blood
Blood (2013) 122 (21): 5086.
https://doi.org/10.1182/blood.V122.21.5086.5086
Published: 2013
Journal Articles

Haemophagocytic Lymphohistiocytosis (HLH) Associated With a Heterozygous PRF1 Mutation Not Previously Described As Pathogenic

Alejandro Arbelaez, MBBS, Laurence Catley, MBBS, FRCPA, FRACP
Journal: Blood
Blood (2013) 122 (21): 4715.
https://doi.org/10.1182/blood.V122.21.4715.4715
Published: 2013